Skip to main content

Visiting Professorships

  • Visiting Professor, University of Alberta, Edmonton, Alberta, Canada, Department of Neurology Grand Rounds, September 27, 2019.
  • Visiting Professor, University of Vermont School of Medicine, Department of Neuroscience Grand Rounds, Burlington, VT, October 4, 2019

Invited Lectures

  • Lecturer, Regeneron Pharmaceuticals, Complement – the New Strategy for Autoimmune Disease, Tarrytown, NY, September 6, 2019.
  • Lecturer, Annual Muscle Study Group Meeting, Complement Inhibition in Myasthenia Gravis, Snowbird, UT, September 22, 2019.
  • Wismer Lecture on Myasthenia Gravis, Complement, A New Paradigm for the Treatment of Myasthenia Gravis, University of Alberta, Edmonton, Alberta, Canada, September 27, 2019.
  • Keynote Address at the 10th Annual Myasthenia Gravis Patient Education Day, Emerging Therapies for the Treatment of Myasthenia Gravis, Edmonton, Alberta, Canada, September 28, 2019.

Presentations

Howard JF Jr, Nowak RJ, Wolfe GI, Benatar MG, Duda PW, MacDougall J, Farzaneh-Far R, Kaminski HJ, the Zilucoplan MG Study Group: Zilucoplan, a Subcutaneously Self-Administered Peptide Inhibitor of Complement Component 5 (C5), for the Treatment of Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial and Open-Label Long-Term Extension.  Paper presented at the 5th Congress of the European Academy of Neurology, Oslo, Norway, June 30, 2019.

Howard JF Jr: The role of complement in the treatment of Myasthenia Gravis.  Paper presented to the 2019 Muscle Study Group Annual Scientific Meeting. September 21, 2019, Snowbird, Utah.

Nowak RJ, Muppidi S, Beydoun SR, O’Brien F, Yountz M, Howard JF Jr for the REGAIN Study Group:  Changes in concomitant immunosuppressive therapy use during a Phase 3 open-label study of eculizumab in adults with generalized myasthenia gravis.  Poster presented at the 92nd Congress of the Deutsche Gesellschaft für Neurologie (DGN), September 25–28, 2019, Stuttgart, Germany.

Moore C, Caughey M, Prieto J, Chopra M, Howard JF Jr,  Gallippi C: Imaging Viscoelasticity of Control and Dystrophic Vastus Lateralis using Quantitative Viscoelastic Response (QVisR) Imaging.  Paper presented at the 2019 IEEE International Ultrasonics Symposium (IUS), Glasgow, Scotland, October 8, 2019.

Moore C, Caughey M, Prieto J, Chopra M, Howard JF Jr, Gallippi C: Texture in Quantitative Viscoelastic Response (QVisR) images reflects compositional differences in control versus dystrophic muscle, in vivo.  Paper presented at the 2019 IEEE International Ultrasonics Symposium (IUS), Glasgow, Scotland, October 9, 2019.

Russo M, Howard JF Jr, Emmet D, Chopra M, Duda P, Ricardo A, Read S, Yi J, Guptil JT: In-depth immune profiling of treatment-naïve myasthenia gravis patients. Paper to be presented at the Annual Scientific Session of the Myasthenia Gravis Foundation of America, Austin, TX, October 16, 2019.

Narayanaswami P, Sanders DB, Guptill JT, Li F, Desai R, Venitz J, Bibeau B, Krueger A, PROMISE-MG Study Group: PROMISE-MG: A Prospective Multicenter Observational Study of the Comparative Effectiveness of Treatments for Myasthenia Gravis: Preliminary Results. Paper to be presented at the Annual Scientific Session of the Myasthenia Gravis Foundation of America, Austin, TX, October 16, 2019.

Rivner M, Quarles B, Pan J, Yu Z, Howard JF Jr, Corse A, Dimachkie M, Jackson C, Vu T, Small G, Lisak R, Belsh J, Lee I, Baute V,  Scelsa S, Fernandes A,  Simmons Z, Swenson A, Barohn R,  Bhavaraju Sanka R,  Gooch C, Ubogu E, Caress J, Mei L, and the LRP4 Study Group: Multicenter study of LRP4 and agrin antibodies in myasthenia gravis (MG). Paper to be presented at the Annual Scientific Session of the Myasthenia Gravis Foundation of America, Austin, TX, October 16, 2019.

Howard JF Jr, Karam C, Yountz M, O’Brien F, Mozaffar T: Long-Term Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis: Responder Analyses. Paper to be presented at the Annual Scientific Session of the Myasthenia Gravis Foundation of America, Austin, TX, October 16, 2019.

Howard JF Jr, Nowak RJ, Wolfe GI, Benatar MG, Duda PW, MacDougall J, Farzaneh-Far R, Kaminski HJ, the Zilucoplan MG Study Group: Zilucoplan, a Subcutaneously Self-Administered Peptide Inhibitor of Complement Component 5 (C5) for the Treatment of Generalized Myasthenia Gravis: Phase 2 Results.  Paper to be presented at the Annual Scientific Session of the Myasthenia Gravis Foundation of America, Austin, TX, October 16, 2019.

Publications

Howard JF Jr, Brill V, Burns TM, Mantegazza R, Bilinska, M, Szczudlik A, Beydoun, S, Diez-Tejedor, E, Piehl, F, Rottoli, M, Van Damme, P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren, K, Guglietta A, de Haard H, Leupin N, Verschuuren, JJGM, Efgartigimod MG Study Group: A randomized, double-blind, placebo-controlled Phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.  Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. [Epub ahead of print]  2019 May 22. PubMed PMID: 31118245.

Agrawal YN, Howard JF Jr, Collichio FA: Management of myasthenia gravis without significant exacerbation during nivolumab therapy for metastatic melanoma: a case report and review of the literature.  Annals of Clinical Oncology [Epub ahead of print] 2019 May 22 DOI: 10.31487/j.ACO.2019.02.01.

Raja S, Howard JF Jr, Juel V, Massey J, Chopra M, Guptil J: Clinical Outcome Measures Following Plasma Exchange for MG Exacerbation. Annals of Clinical and Translational Neurology [Epub ahead of print] 2019 September DOI:10.1002/acn3.50901.

Moore C, Caughey M, Chopra M, Howard Jr JF, Gallippi C: Estimating Degree of Mechanical Anisotropy in Dystrophic and Control Rectus Femoris in Boys Using VisR Ultrasound. Proceedings of the 2017 IEEE International Ultrasonics Symposium (IUS). (in press).

Awards

European Academy of Neurology 2019 Investigator Award (for presentation at the 5th Congress of the European Academy of Neurology, Oslo, Norway)